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p38 MAPKThe PI3K-PDK1-PKB/Akt (PI3K, phosphoinositide-3 kinase; PDK1, phosphoinositide-dependent protein
kinase 1; PKB, protein kinase B) signaling pathway plays a critical role in a variety of biological processes
including cell survival, growth and proliferation, metabolism and organogenesis. Previously, we generated
Akt1-deﬁcient mice and found high neonatal mortality with unknown causes. Here we report that histological
analysis of Akt1-deﬁcient embryos and newborns revealed heart defects and decreased cell proliferation.
Echocardiographic study of Akt1-deﬁcient mice indicated decreased heart function. Further investigation
revealed that Akt1 deﬁciency caused substantial activation of p38MAPK in the heart. Breeding the Akt1-
deﬁcient mice to mice that were heterozygous for a null p38α partially rescued the heart defects, signiﬁcantly
decreased post-natal mortality, and restored normal patterns of cardiomyocyte proliferation. Our study
suggests that Akt1 is essential for heart development and function, in part, through suppression of p38MAPK
activation.g 210061, China. Fax: +86 25
g).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
The PI3K-PDK1-Akt/PKB (PI3K, phosphoinositide-3 kinase; PDK1,
phosphoinositide-dependent protein kinase 1; PKB, protein kinase B)
signaling pathway plays a critical role in a variety of biological
processes, such as cell survival, growth and proliferation, metabolism
and organogenesis (Brazil et al., 2004; Dummler and Hemmings,
2007; Mora et al., 2004; Woodgett, 2005; Yang et al., 2004). The
importance of this signaling pathway in animal development has been
demonstrated by a multitude of lethal phenotypes in mouse models
carrying null mutations of key components of this pathway. Deletion
of Igf1r caused neo-natal mortality (Liu et al., 1993). Inactivation of
PI3K catalytic subunits of p110α and p110β resulted in embryonic
mortality at around embryonic day 10.5 (E10.5) and E3.5, respectively
(Bi et al., 2002; Bi et al., 1999; Okkenhaug and Vanhaesebroeck, 2003)
and loss of PDK1 gave rise to nonviable embryos at E9.5 (Lawlor et al.,
2002). Previously, we found that double knockout (dKO)mice of Akt1/
PKBα and Akt3/PKBγ were embryonic lethal at approximately E12.5
and displayed vascular defects (Yang et al., 2005).
Earlier studies by us and others revealed high post-natal mortality
of Akt1-deﬁcient mice but the underlying mechanisms remain
undeﬁned (Cho et al., 2001; Yang et al., 2003). The present dataexplore the mechanism by which Akt1 deﬁciency causes early death.
Histological investigation identiﬁed heart defects and echocardio-
graphic study indicated decreased heart function in Akt1mutantmice.
The mice also displayed decreased cardiomyocyte proliferation.
Further analysis indicated that loss of Akt1 activates the p38MAPK
in the hearts of Akt1-null mice. Consistent with causality, when
heterozygous nulls for p38αwere bred into the Akt1-null background,
heart developmental defects and post-natal mortality were partially
rescued, and aberrant levels of cardiomyocytes proliferation were also
restored. The results of our study demonstrate that Akt1 is essential
for heart development and functions partially through suppression of
p38 MAPK activation.Materials and methods
Mice and animal care
Akt1/Pkbα knockout mice have been described previously and were
backcrossed toB6background formore than10generations (Yang et al.,
2003). p38α knockout mice were provided by Merck and are in a B6
background (Mudgett et al., 2000). The experimental animal facility has
been accredited by AAALAC (Association for Assessment and Accred-
itation of Laboratory Animal Care International) and the IACUC
(Institutional Animal Care and Use Committee) of Model Animal
Research Institute of Nanjing University approved all animal protocols
used in this study.
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Brieﬂy, hearts or embryos were ﬁrst washed with cold PBS and
then ﬁxed in formalin overnight at 4 °C. The samples were processed
successively by (a) a 30-min wash in PBS at 4 °C; (b) 1-h incubations
in 70%, 80%, 95% ethanol and three 1-h incubations in 100% ethanol at
room temperature (RT); (c) three 20-min incubations in xylene at RT;
(d) a 1-h incubation in parafﬁn/xylene (1:1) at 65 °C; and (e) three
1-h incubations in fresh parafﬁn at 65 °C. The processed samples were
then embedded in parafﬁn, sectioned (7 μm thick) and HE stained
following standard protocols. For IF staining, sections were dewaxed
and processed for antigen retrieval by incubating in 0.5 mM sodium
citrate buffer (pH 6.0) for 25 min in steamer. The sections were then
incubated in blocking solution (5% goat serum in TBST buffer) for
30 min at RT, washed three times, and then incubated overnight at
4 °C with primary antibody diluted in blocking solution. The next day,
sections were incubated in a 1:500 dilution of Alexa Fluor 488 goat-
anti-rat IgG and Alexa Fluor 543 goat-anti-rabbit IgG secondary
antibody for 1 h at RT. After washing three times with PBS, images
were obtained with a Research Fluorescence Microscope (Olympus,
Japan).
BrdU incorporation
Bromodeoxyuridine (BrdU, Sigma) was administrated to E14.5
pregnant mice by intraperitoneal injection (1 mg per 10 g body
weight), and the mice were sacriﬁced after 2 h. Embryos were
dissected out, ﬁxed in 4% paraformaldehyde (PFA) for 2 h at RT with
gentle shaking, processed as above and embedded in parafﬁn for
sectioning and immunoﬂuorescence staining.
Cell culture
For MEFs (murine embryonic ﬁbroblasts): MEFs were generated
from E13.5 embryos from heterozygous mutant Akt1mating andwere
maintained in DMEM plus 10% fetal bovine serum (Hyclone) as
previously described. Cells of the ﬁrst 5 generations were used.
For cardiomyocytes: Cardiomyocytes were isolated as previously
described (Borger and Essig, 1998). Brieﬂy, E14.5 embryonic hearts
were dissected and atria were removed. Ventricles were excised to
1×1 mm pieces in collagenase (type 2, Sigma). After incubation at
37 °C for 10 min, supernatants were ﬁltered and cells were collected
by centrifugation. These cells were cultured in DMEM plus 10% fetal
bovine serum (Hyclone). Most of the cells were beating after 24 h of
culture.
All cells are used forWestern blotting analyses after 6 h serum-free
starvation.
Western blotting analysis and antibodies
Hearts were dissected and snap-frozen in liquid nitrogen until use.
Tissue/cell lysates were prepared in lysis buffer (20 mM Tris, 150 mM
NaCl, 10% glycerol, 20 mM glycerophosphate, 1% NP40, 5 mM EDTA,
0.5 mM EGTA, 1 mM Na3VO4, 0.5 mM PMSF, 1 mM benzamidine,
1 mM DTT, 50 mM NaF, 4 M leupeptin, at pH8.0). Samples were
resolved by 10% SDS-PAGE and transferred to PVDF membranes
(Millipore). Membranes were blocked with TBST (50 mM Tris,
150 mM NaCl, 0.5 mM Tween-20, pH 7.5) and then incubated with
primary antibodies overnight. Mouse Akt1, 2 and3 antibodies were
generated previously (Yang et al., 2003). The following antibodies
were purchased from Cell Signaling Technology (CST): total Akt
(9272), pThr308 phospho-Akt antibody (9275), pSer473 phospho-Akt
antibody (9271), Erk (9102), phospho-Erk (9101), JNK (9252),
phospho-JNK (9251), p38 (9212), phosphor-p38 (9211), p38
(9218), TAK1 (4505), phospho-TAK1 Thr184/187 (4531), phospho-
TAK1 Ser412 (9339), phosphor-ASK1 (3761). Nkx2.5 (H-114, sc-14033) and total ASK1 (H-300, sc-7931) were purchased from Santa
Cruz. Pan-actin antibody (MS-1295-P0) and HRP-linked secondary
antibodies (Prod #31460 and Prod #31430) were purchased from
Thermos Scientiﬁc.
Echocardiography (Echo)
Echo was performed with Vevo 770 UBM (VisualSonics, Toronto,
ON, Canada) that possesses a single-element mechanical transducer
with a center frequency of 30 MHz and a frame rate of 30 Hz.
Echocardiograms to assess systolic function were performed using
M-mode and two-dimensional measurements. For Echowith neonatal
mice, all male and female pups were imaged at postnatal 2 days (P2).
Unanesthetizedmicewere placed on an imaging table under a heating
plate, and were lightly restrained in a left lateral decubitus position.
Fractional shortening (FS), a surrogate of systolic function, was
calculated from left ventricle dimensions as follows: FS 1⁄4 ((EDD 2
ESD)/EDD)×100% and ejection fraction (EF) was calculated from two-
dimensional images.
Statistical analysis
The results are presented as the mean±SEM values. Statistical
calculations were performed using a standard t-test of variables with
95% conﬁdence intervals. A value of Pb0.05(*) was considered
statistically signiﬁcant and Pb0.01(**) statistically very signiﬁcant.
Results
Akt1 is the dominant isoform in the heart
In mice, there are three Akt isoforms named Akt1/PKBα, Akt2/
PKBβ and Akt3/PKBγ, respectively (Brazil et al., 2004; Dummler and
Hemmings, 2007; Yang et al., 2004). We ﬁrst investigated the protein
levels of these three Akt proteins in WT and Akt1 deﬁcient hearts by
Western blotting analysis. While Akt2 and Akt3 levels in Akt1mutant
heart were normal compared with WT controls, the total and
phospho-Akt levels decreased signiﬁcantly (Fig. 1). Taken together,
these results have demonstrated that Akt1 is the dominant Akt
isoform in mouse heart suggesting a more important role than that of
Akt2 or Akt3 in heart.
Akt1 mutant mice displayed high post-natal mortality, heart defects,
impaired heart function
Previously, we and others observed that a signiﬁcant number of
Akt1 null mice showed very early or early mortality (Cho et al., 2001;
Yang et al., 2003). Themajority of Akt1 deletionmice die within 4 days
after birth (Fig. 2A and Table 1). Thus, inactivation of Akt1 reduced
survival of mice. The high mortality of Akt1-deﬁcient mice prompted
us to investigate the underlying mechanisms resulting in death.
Previously, we found that Akt1−/−Akt3+/− mice have cardiovascular
problems (Yang et al., 2005). Therefore, we focused on heart
development in Akt1-deﬁcient mice. Histological studies of wild-
type (WT) and Akt1-null littermates at embryonic day 14.5 (E14.5)
revealed ventricular septal defects (VSD) in all four Akt1-null embryos
analyzed, while we found only one subtle VSD in three WT embryos
(Fig. 2B, C). A comprehensive examination of newborn Akt1 mutants
revealed heart defects, including atrial septal defects (ASD), VSD, both
ASD and VSD, while hearts of WT mice are normal (Fig. 2D–G and
Table 2). Moreover, some hearts of Akt1-null mice also displayed thin
myocardium (Fig. 2C, F, G). In addition, some of the hearts in Akt1-
deﬁcient mice displayed a dilated morphology (Fig. 2E, G). Further-
more, we assessed the heart function of Akt1 mutant mice with
echocardiography and found decreased heart function at 2 days after
birth (P2), which may contribute to the neonatal mortality (Table 3).
Fig. 1. Analysis of Akt proteins in hearts from WT and Akt1-deﬁcient mice. (A) Western blot analysis of Akt isoforms. Hearts were dissected from four WT and four Akt1-deﬁcient
newborn mice (the eight animals were chosen randomly). P-AktS473 represents the phosphorylation (active) levels of total Akt. (B) Quantiﬁcation of total Akt and phospho-Akt
(active Akt) (**Pb0.001 versus WT).
Fig. 2. Post-natal mortality and heart defects in Akt1-deﬁcient mice. (A) Survival curve of WT and Akt1−/−mice. More than half of Akt1−/−mice died in the ﬁrst four days after birth
(**Pb0.01 versus WT). (B, C) Histological study of hearts fromWT and Akt1−/− embryos at E14.5 by hematoxylin–eosin staining. The arrowhead indicates a VSD. (D–G) Histological
analysis of hearts from newborn WT and Akt1−/−mice. The arrowheads indicate muscular VSD (E), a membranous VSD (F) and an ASD (G). Abbreviations: LA, left atrium; RA, right
atrium; LV, left ventricle; RV, right ventricle; ASD, atrial septal defect; VSD, ventricular septal defect. The pictures were taken under the same experimental and light conditions. Bars,
50 μm.
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Table 1





P1(newborns) 65 (20.6%) 178 (56.5%) 72 (22.9%) 315
2-4weeks 199 (30.3%) 394 (60.0%) 64 (9.7%) 657
67.8% of Aktl−/− mice were lost.
Table 2
Frequency of congenital heart defects in P1 Aktl−/− hearts.
Genotype
Type of congenital heart defects
Normal TotalASD VSD ASD+VSD
Akt1–/– 11 (28.9%) 7 (18.4%) 7 (18.4%) 13 (34.2%) 38
WT 0 0 0 13 (100%) 13
Abbreviations: VSD: ventricular septal defects; ASD: atria septal defects.
Table 3
Echocardiographic measurements at P2.
WT (n=19) Akt1–/– (n=15)
IVS;d (mm) 0.28±0.036 0.27±0.033
LVID;d(mm) 1.21±0.11 1.25±0.18
LVPW;d (mm) 0.30±0.035 0.26±0.034*
IVS;s (mm) 0.36±0.049 0.32±0.073
LVID;s (mm) 0.74±0.13 0.86±0.21*
LVPW;s (mm) 0.38±0.053 0.32±0.072*
LV Vol;d (mm) 3.49±0.83 3.93±1.44
LV Vol;s (mm) 0.99±0.46 1.57±1.01*
EF (%) 72.76±7.23 62.76±13.64**
FS (%) 38.88±6.46 32.04±9.76**
LVMass (mg) 4.17±0.76 3.94±1.11
Mice were measured at post-natal day 2 (P2). The results are presented as mean±SEM
values. Abbreviations: IVS, interventricular septum; LVID, left ventricular internal
dimension; LVPW, left ventricular posterior wall; LV, left ventricle; EF, ejection fraction;
FS, fractional shortening. *Pb0.05. **Pb0.01 versus WT.
Fig. 3. Cell proliferation assay by BrdU labeling. Immunohistochemical (IHC) staining of
(E) Quantiﬁcation of total BrdU positive nuclei/total nuclei (**Pb0.01 vs. WT, WT: n=3; Ak
387Z. Chang et al. / Developmental Biology 347 (2010) 384–391Whereas, we found that the heart function and the ratio of heart
weight to body weight of the survival adult Akt1 mutant mice were
comparable toWT control (Fig. S1 and Table S1). These results, for the
ﬁrst time, demonstrate that Akt1 is essential for heart development
and function.
Decreased cell proliferation in Akt1-deﬁcient heart
We assessed cardiac cell proliferation in WT and Akt1-null mice by
BrdU and phospho-histone H3 (pH3) immunohistochemical (IHC)
staining with E14.5 embryos. Cell proliferation was markedly reduced
in Akt1-null heart compared with the WT control (Fig. 3 and S2).
We also studied apoptosis in WT and Akt1-null hearts by TUNEL
assay. We failed to detect a signiﬁcant difference between these two
genotypes (data not shown).
Substantial activation of p38MAPK signaling pathway in Akt1-deﬁcient
heart
To understand the molecular mechanisms underlying the heart
defects in Akt1-null mice, we analyzed the activity of MAPKs such as
Erk, JNK and p38 in the hearts of newborn mice. There was no
difference in Erk or JNK activity between the WT control and Akt1
mutant mice, but p38 MAPK activity was activated substantially
(Fig. 4A, B). Further analysis of embryos indicated that p38 MAPK
activity was signiﬁcantly higher in Akt1 mutant hearts than in WT
controls at developmental stage as early as E12.5 (Fig. 4C, D). In
addition, we cultured the MEFs and cardiomyocytes isolated fromWT
and Akt1 null embryos and examined the levels of active p38MAPK in
these cells. The results were similar to those with the whole hearts
and indicated increased p38MAPK activation in Akt1mutantMEFs and
cardiomyocytes (Fig. 4E–H).
Next, we wanted to understand how p38MAPK is activated by
upstream kinases (Johnson and Lapadat, 2002;Wang, 2007). To better
investigate the upstream signaling of p38MAPK in the absence of
Akt1, we analyzed WT and Akt1mutant MEFs. Both MKK3 and MKK6,
once phosphorylated by TAK1, can activate p38 MAPK through direct
phosphorylation (Fig. 4I). While total TAK1 was comparable in WT
and Akt1 mutants, phospho-TAK1 (T184/T187 and S412) levels wereheart sections at E14.5 and proliferating cell were indicated by arrowheads (A–D).
t1−/−: n=4).
388 Z. Chang et al. / Developmental Biology 347 (2010) 384–391signiﬁcantly higher in Akt1 mutants than WT controls (Fig. 4J, K).
p38MAPK can also be activated by another upstream kinase, ASK1
that is negatively regulated by Akt through direct phosphorylation atFig. 4. Analysis of Akt and MAPK signaling pathway in hearts, MEFs and cardiomyocytes from
Erk, JNK and p38 in WT and Akt1−/− hearts. (A) Four hearts were from WT newborn mi
randomly). Note that in Akt1-deﬁcient hearts, p38MAPK is highly active compared to its nea
(**Pb0.01 versusWT). (C) Examination of p38MAPK activity in embryos at different developm
as early as E12.5. (D) Quantiﬁcation of active p38MAPK in (C). (E) Analysis of p38MAPK
signiﬁcantly high in Akt1−/−MEFs. (F) Quantiﬁcation of (E). (G) Phospho-p38 levels in isolat
(I) Regulation of p38MAPK signaling pathway. (J) Analysis of upstream kinase activation of p
S412) levels were higher, while phospho-ASK1 (S83) levels were lower in Akt1−/− MEFs. (serine 83 (S83) (Fig. 4I) (Kim et al., 2001; Liao and Hung, 2003;
Tobiume et al., 2001). We, therefore, examined ASK1 S83 phosphor-
ylation in MEFs and the results displayed decreased phospho-ASK1WT and Akt1-deﬁcient mice. (A–D)Western blot analysis of the three major MAPKs of
ce, and four were from Akt1-deﬁcient newborn mice (the eight animals were chosen
rly undetectable level in the WT. (B) Quantiﬁcation of total and active p38MAPK in (A)
ental stages. The increased activity of p38MAPK in Akt1−/− hearts is already detectable
phosphorylation in MEFs. Phospho-p38 levels are hard to detect in WT MEFs but are
ed cardiomyocytes. The results were similar to those of MEFs. (H) Quantiﬁcation of (G).
38MAPK inWT and Akt1−/−MEFs. Compared with theWT, phospho-TAK1 (T174/T187/
K) Quantiﬁcation of levels of kinase activation in (J).
Table 4
Frequency of progeny from Akt1+/−p38α+/− intercrosses.
Genotype (total number: 526)
Akt1−/− Akt1−/− Akt1−/− Akt1+/− Akt1+/− Akt1+/− Akt1+/+ Akt1+/+ Akt1+/+
p38α+/+ p38α+/− p38α−/− p38α+/+ p38α+/− p38α−/− p38a+/− p38α+/– p38α–/–
No. 31 64 0 108 183 0 48 92 0
Actual % 5.9% 12.2% 0 20.5% 34.8% 0 9.1% 17.5% 0
Theoretical% 8.3% 16.7% 0 16.7% 33.3% 0 8.3% 16.7% 0
~30% of Akt1−/−p38α+/− mice were lost.
389Z. Chang et al. / Developmental Biology 347 (2010) 384–391levels in Akt1 mutants compared to controls (Fig. 4I–K). Taken
together, these results are consistent with the hypothesis that Akt1
negatively regulates p38MAPK activity, at least partially, through
TAK1 and ASK1 kinases.
In addition, we analyzed p38 MAPK activity in other organs and
found a slight increase in the liver of Akt1-deﬁcient mice (Fig. S3).
Histological analysis of liver in Akt1-deﬁcient mice revealed normal
morphology (data not shown).
Haploinsufﬁciency of p38α partially rescues post-natal mortality and
frequency of heart defects in Akt1 nulls
Our results suggested that loss of Akt1 causes p38MAPK activation in
the heart and that this may disrupt normal heart development, thereby
increasing mortality. To test whether deletion of p38 could rescue the
phenotype, we crossed Akt1 and p38α null mice. Because p38α−/−mice
are embryonic lethal, we only obtained Akt1−/−p38α+/−mice (Adams
et al., 2000;Mudgett et al., 2000;Tamura et al., 2000).Westernblotwere
performed and indicated decreased activity of p38 (Fig. S4). Haploin-
sufﬁciency of p38α reduced post-natal mortality of Akt1 nulls from
67.8% to30.4% (Table 4). Thus, p38α in the heterozygous state conferred
viability on Akt1-deﬁcient mice. Histological analysis of the hearts from
Akt1−/−p38α+/− mice also demonstrated signiﬁcantly decreased
occurrence of cardiac septal defects from 65.8% to 45.2% (Table 5). In
particular, we studied cardiomyocyte proliferation by Nkx2.5 and BrdU
labeling in WT, Akt1−/− and Akt1−/−p38α+/− mice with Nkx2.5
antibody speciﬁcally recognizing cardiomyocytes in mid-term embry-
onic heart (Zeisberg et al., 2005; Zhou et al., 2009). We found that
proliferating cardiomyocytes (Nkx2.5 and BrdU double positive) were
comparable in WT and Akt1−/−p38α+/− mice, but were signiﬁcantly
reduced in Akt1−/−mice (Fig. 5A–E). These results indicated that half-
deletion of p38α also partially rescued cardiomyocyte proliferating
defects in Akt1mutant mice.
Discussion
In the past decade, Akt's function in hypertrophy and myocardial
protection in adult mice has been extensively explored (Condorelli
et al., 2002; Cook et al., 2002; DeBosch et al., 2006a; Kovacic et al.,
2003; Murakami et al., 2004; Muslin and DeBosch, 2006; O' Neill and
Abel, 2005; Olson and Schneider, 2003; Shioi et al., 2002; Shiojima
et al., 2005; Shiojima and Walsh, 2002; Shiojima and Walsh, 2006;
Taniyama et al., 2005; Walsh, 2006). Most of these studies were
performed in mice with Akt over-expression in cardiomyocytes.
Recently, a report from Muslin's group has demonstrated Akt1'sTable 5
Frequency of congenital heart defects in Akt1−/−p38a+/− mice.
Type of congenital heart defects
Genotype ASD VSD ASD+VSD Normal Total
Akt1−/− p38a+/− 9 (29%) 3 (9.7%) 2 (6.5%) 17 (54.8%) 31function in physiological cardiac growth using Akt1 knockout mice
(DeBosch et al., 2006b). Nonetheless, the role of Akt1 in embryonic
heart development is much less studied and our work indicates that
Akt1 also plays an important role during embryogenesis, in particular
in heart development.
In this study, we have uncovered an important role of Akt1 in
regulating heart development and function. Previously, we and others
observed that Akt1-deﬁcient mice displayed partial lethality without
knownmechanism (Cho et al., 2001; Yang et al., 2003). We also found
that nearly all Akt1−/−Akt3+/− were lost shortly after birth (Yang
et al., 2005). Collectively, these studies suggest that defective heart
development and abnormal heart function might be the main cause
for the mortality of Akt1-null and Akt1/Akt3 compound mutant mice.
Previously, we identiﬁed a placental insufﬁciency resulting from
reduced placental mass and vasculature in Akt1 deﬁciency mice (Yang
et al., 2003). Therefore, it is possible that placental defects may
contribute to abnormal heart development in Akt1 deﬁciency mice.
Nonetheless, study of mice with heart-speciﬁc deletion of PDK1, an
essential upstream kinase of Akt revealed severe heart defects that
give rise to embryonic lethality (Feng et al., 2010). Because Akt
proteins are major down-stream targets of PDK1, abnormal heart
development in cardiac-speciﬁc PDK1 deletion mice supports this
study indicating that Akt plays a critical role in heart development.
Mechanistically, the cause for the developmental defects in Akt1-
deﬁciency heart could be attributed to aberrant activation of
p38MAPK signaling. Previously, it was reported that p38MAPK
negatively regulated cardiomyocyte proliferation (Engel et al., 2006;
Engel et al., 2005). Our results are in consistency with these studies.
We found decreased cardiomyocyte proliferation in Akt1-deﬁcient
mice and half-deletion of p38α in Akt1-deﬁciency mice signiﬁcantly
enhanced cardiomyocyte proliferation and rescued heart defects. One
of the upstream kinases of p38 MAPK is ASK1 that is negatively
regulated by Akt through phosphorylation. Consistently, we observed
signiﬁcantly reduced ASK1 phosphorylation in Akt1-null MEFs, which
in turn, contributed to p38 MAPK activation. Meanwhile, we also
found enhanced activity of TAK1 that activates the other two
upstream kinases of p38 MAPK, MKK3 and MKK6. How TAK1 activity
is enhanced in the absence of Akt1 needs further investigation.
In the future, modulation of the activity of these two kinases
(enhancement of Akt activation and reduction of p38 MAPK
activation) may have therapeutic implications to improve the
situation of human heart defects.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2010.08.033.
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Fig. 5. BrdU assay in E14.5WT, Akt1−/− and Akt1−/−p38a+/− hearts. (A–C) Nkx2.5 antibody labeled the nuclei of cardiomyocytes (in green). BrdU positive nuclei were labeled in red.
Double positive nuclei are in yellow. (D) and (E) Quantiﬁcation of total BrdU positive cells and Nkx2.5/BrdU double positive cells, respectively (*Pb0.05 versus Akt1−/−; **Pb0.01
versus WT; WT: n=4, Akt1−/−: n=5, Akt1−/−p38a+/−: n=3).
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